IAA Journal of Scientific Research 11(3):7-13, 2024.
©IAAJOURNALS
https://doi.org/10.59298/IAAJSR/2024/113.713

www.iaajournals.org
ISSN: 2636-7319
IAAJSR:113.713

The Relationship between Genetics and Diabetes: A Comprehensive Review

Kibibi Muthoni L.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Diabetes mellitus is a complex and chronic metabolic disorder that affects millions globally. This review explores the intricate relationship between genetics and diabetes, focusing on the roles of genetic predisposition in various forms of diabetes, including type 1 diabetes (T1D), type 2 diabetes (T2D), and monogenic diabetes. Genetic factors significantly influence the onset and progression of diabetes, with both polygenic and monogenic forms contributing to the disease. For T1D, autoimmune processes triggered by genetic and environmental factors lead to insulin deficiency, while in T2D, a polygenic interaction of genetic susceptibility and lifestyle factors results in insulin resistance. Monogenic forms of diabetes, such as Maturity Onset Diabetes of the Young (MODY) and neonatal diabetes, are caused by mutations in single genes. This review also highlights the growing field of epigenetics, which examines how environmental factors can modify gene expression and impact diabetes risk. Gene-environment interactions, personalized medicine, and genetic testing are explored as critical components in improving diabetes management and prevention strategies. The review concludes by outlining future research directions, including the potential of gene therapy and epigenetic therapies in diabetes treatment.

Keywords: Diabetes mellitus, Genetics, Type 1 diabetes, Type 2 diabetes, Monogenic diabetes, Epigenetics.

INTRODUCTION

Diabetes mellitus is a multifaceted and chronic metabolic disorder characterized by persistent hyperglycemia (elevated blood glucose levels), which results from defects in insulin production, insulin action, or a combination of both [1]. Insulin, a hormone produced by the pancreas, plays a key role in regulating blood sugar levels by facilitating glucose uptake by cells [2]. When insulin secretion is inadequate, or the body's cells become resistant to its effects, glucose remains in the bloodstream, leading to the condition known as diabetes [3]. Diabetes is not a singular disease but a spectrum of disorders with different causes, manifestations, and genetic predispositions [4]. It is broadly classified into type 1 diabetes (T1D), type 2 diabetes (T2D), and other less common forms, including gestational diabetes and monogenic diabetes [5]. While environmental and lifestyle factors such as diet, physical inactivity, and obesity are well-known contributors to the development of diabetes, genetics plays a crucial role in its onset and progression [6]. Understanding the genetic underpinnings of diabetes is essential for developing targeted interventions and personalized treatment strategies [7].

The role of genetics in diabetes varies across the different types of the disease. In T1D, an autoimmune condition, the immune system mistakenly attacks insulin-producing beta cells in the pancreas, leading to absolute insulin deficiency [8]. In this form, genetic predisposition combined with environmental triggers plays a central role in disease development [9]. In contrast, T2D, which accounts for the majority of diabetes cases worldwide, is characterized by insulin resistance and is often associated with obesity and aging. T2D is polygenic, meaning that multiple genes contribute to an individual's susceptibility to developing the condition [10]. Additionally, monogenic diabetes, which includes subtypes like Maturity Onset Diabetes of the Young (MODY) and neonatal diabetes, is caused by mutations in a single gene and often presents in younger individuals [11]. This review aims to delve into the intricate relationship

between genetics and diabetes, exploring how genetic predisposition influences the onset of different types of diabetes, the role of gene-environment interactions, and the potential for personalized medicine in managing the disease [12]. By examining the genetic basis of T1D, T2D, and monogenic diabetes, this review will provide a comprehensive understanding of how inherited factors contribute to diabetes pathophysiology and the broader implications for prevention and treatment [13].

Type 1 Diabetes (T1D) and Genetics

Type 1 Diabetes (T1D) is an autoimmune disorder where the immune system attacks and destroys insulin-producing beta cells in the pancreas, leading to absolute insulin deficiency [14]. Insulin is crucial for regulating blood glucose levels, and without sufficient insulin, glucose accumulates in the bloodstream, leading to hyperglycemia and diabetes. T1D typically manifests during childhood or adolescence, but can develop at any age [15]. Unlike Type 2 Diabetes, which is heavily influenced by lifestyle factors like diet and physical activity, T1D is largely driven by genetic susceptibility and autoimmune processes [16]. Genetic predisposition plays a pivotal role in the development of T1D, with key loci associated with T1D susceptibility identified. The Human Leukocyte Antigen (HLA) complex and several non-HLA genes contribute to T1D susceptibility, including the INS (Insulin Gene) mutation, PTPN22 (Tyrosine Phosphatase) gene, and CTLA4 (Cell Translocation and Leukocytes) gene. Family aggregation and twin studies also contribute to T1D susceptibility [17]. Siblings of individuals with T1D have a 6-10% chance of developing the disease, while parent-child risk is approximately 3-4% for mothers and 6-8% for fathers [18]. Concordance rates in identical (monozygotic) twins provide further insight into the genetic influence on T1D. T1D is influenced by genetics but not solely determined by inheritance [19]. Understanding the genetic factors behind T1D can help identify high-risk individuals and pave the way for preventive strategies or early interventions in the future.

Type 2 Diabetes (T2D) and Genetics

Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and relative insulin deficiency, leading to elevated blood glucose levels [20]. It accounts for 90-95% of all diabetes cases worldwide and is heavily influenced by lifestyle factors such as obesity, poor diet, physical inactivity, and aging [21]. Genetic predisposition also plays a significant role in the development of T2D, with individuals with a family history of T2D at a significantly higher risk of developing the condition. T2D is a polygenic disorder, meaning multiple genes, each contributing a small effect, collectively increase an individual's risk of developing the disease [22]. Some well-established genetic variants associated with T2D include TCF7L2, PPARG, and FTO. TCF7L2 encodes a transcription factor involved in insulin secretion and glucose metabolism, while PPARG encodes a nuclear receptor that plays a crucial role in regulating fat metabolism, insulin sensitivity, and glucose homeostasis [23]. FTO variants are associated with a higher body mass index (BMI), which is a major risk factor for T2D. T2D is highly heritable, with genetic factors accounting for a substantial proportion of the risk of developing the disease. First-degree relatives of individuals with T2D have a 40% lifetime risk of developing the disease, compared to a much lower risk in the general population [24]. Twin studies show a high concordance rate for identical (monozygotic) twins with T2D, highlighting both genetic and environmental contributions. Ethnic and population variations also contribute to T2D prevalence, with some populations displaying a much higher genetic predisposition to the disease [25].

Monogenic Diabetes: MODY and Neonatal Diabetes

Maturity Onset Diabetes of the Young (MODY) is a rare, hereditary form of diabetes that typically presents in adolescence or early adulthood before the age of 25. It differs from Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D) in several important ways [26]. MODY results from mutations in a single gene, meaning it follows an autosomal dominant inheritance pattern, with affected individuals having a 50% chance of passing the condition to their offspring. It is often misdiagnosed as either T1D or T2D because it shares some clinical features with both types, such as high blood glucose levels, but is distinct because it does not involve autoimmune destruction of beta cells (as in T1D) or significant insulin resistance (as in T2D). Common MODY gene mutations include HNF1A Mutation (MODY3), HNF4A Mutation (MODY1), and GCK Mutation (MODY2) [27]. HNF1A-MODY is highly sensitive to sulfonylureas, making insulin therapy unnecessary for many patients in the early stages of the disease. HNF4A-MODY is similar to HNF1A, affects insulin secretion and leads to more pronounced diabetes. GCK mutations result in a mild form of hyperglycemia, often stable and asymptomatic throughout life [28]. Neonatal

diabetes is a rare monogenic form of diabetes that presents within the first six months of life, distinguishing it from T1D. Common genetic mutations include KCNJ11 Mutation, which affects potassium channels in pancreatic beta cells, leading to a lack of insulin release and persistent hyperglycemia. Genetic testing can help differentiate neonatal diabetes from other forms of diabetes, guiding both acute management and long-term care strategies.

Epigenetics and Diabetes

Epigenetics refers to heritable changes in gene expression, driven by external factors such as diet, exercise, stress, and exposure to environmental toxins [10]. These changes can significantly influence the onset, progression, and severity of both Type 1 and Type 2 diabetes (T1D and T2D). Epigenetic modifications occur through mechanisms such as DNA methylation, histone modification, and non-coding RNAs, which regulate how genes are expressed. These changes affect how cells function, especially in key organs involved in glucose regulation, such as the pancreas, liver, muscle, and fat tissue. Epigenetic changes are increasingly recognized as important contributors to the pathogenesis of Type 2 Diabetes (T2D), where a combination of genetic predisposition and environmental factors lead to insulin resistance and impaired insulin secretion [19]. Epigenetic mechanisms, such as DNA methylation and histone modifications, play a crucial role in how these factors interact and contribute to the development of the disease. Fetal programming, where epigenetic changes can occur early in fetal development, can induce epigenetic modifications in the developing fetus, potentially predisposing the individual to metabolic disorders, including T2D, later in life. Transgenerational inheritance of epigenetic changes is another fascinating aspect of epigenetics, where environmental conditions and lifestyle choices can influence the health and disease risk of subsequent generations. Studies have shown that individuals exposed to famine during critical periods of development have altered epigenetic markers, particularly in genes related to glucose and lipid metabolism, increasing their risk of developing T2D and other metabolic disorders [23]. Understanding the role of epigenetics in diabetes opens up new avenues for therapeutic interventions aimed at reversing or modifying harmful epigenetic marks, potentially providing more personalized treatment options for individuals at risk of developing diabetes.

Gene-Environment Interactions

Gene-environment interactions are crucial in understanding both Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D). In T1D, environmental triggers like viral infections, early-life dietary factors, and vitamin D deficiency play a critical role in triggering the autoimmune response that leads to beta-cell destruction [2]. These interactions are particularly important for developing preventive strategies, therapeutic interventions, and disease management, particularly in those who are genetically vulnerable. T1D is an autoimmune disorder where the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. While genetics establish the underlying risk of diabetes, environmental factors such as diet, physical activity, viral exposure, and obesity often serve as catalysts for the expression of that genetic risk [18]. A deeper understanding of these gene-environment interactions provides insight into preventive strategies, therapeutic interventions, and disease management, particularly in those who are genetically vulnerable. Type 2 Diabetes (T2D) is characterized by insulin resistance and eventual failure of beta cells to secrete adequate insulin. While genetics strongly influence an individual's susceptibility to T2D, lifestyle factors such as diet, physical inactivity, and obesity play a significant role in determining whether the disease will manifest, especially in genetically susceptible individuals [28]. Gene-environment interactions in T2D are particularly important because lifestyle interventions can mitigate genetic risk. Gene-environment interactions are critical to understanding both T1D and T2D. In T1D, environmental triggers such as viral infections, early dietary exposures, and vitamin D levels interact with genetic predisposition to initiate autoimmune processes that destroy insulin-producing cells. In T2D, lifestyle factors like diet, obesity, and physical activity interact with genetic susceptibility to modulate the risk and progression of insulin resistance and beta-cell failure [7].

Genetic Testing and Personalized Medicine

Personalized medicine in diabetes management is a powerful approach that uses genetic testing and pharmacogenomics to provide precise diagnosis, early detection, and tailored treatment strategies. This approach focuses on individual genetic makeup to optimize care and improve outcomes for patients with various forms of diabetes, such as Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young (MODY), and neonatal diabetes. Genetic screening for MODY and neonatal

diabetes can identify specific gene mutations that cause impaired insulin secretion, leading to more appropriate treatment plans [21]. For example, patients with MODY caused by HNF1A mutations may respond well to oral medications that stimulate insulin secretion, rather than insulin therapy. Pharmacogenomics in T2D is transforming the treatment of T2D by identifying variants that affect drug metabolism, helping clinicians personalize treatment plans to enhance effectiveness, minimize side effects, and prevent complications. Genetic testing can help clinicians determine the appropriate dosage or switch to alternative therapies for patients with specific polymorphisms in the GLP-1R or DPP-4 genes. Advances in genetic research and pharmacogenomics have made personalized medicine a viable approach for diabetes management. Genetic screening for MODY and neonatal diabetes allows for accurate diagnosis and tailored treatments, such as the use of oral medications instead of insulin [16]. As genetic testing becomes more accessible, personalized medicine is likely to become a cornerstone of diabetes care, enabling more precise and effective treatments for patients with varying genetic backgrounds and disease presentations.

Future Directions and Research Opportunities

Ongoing research continues to unravel the complex relationship between genetics and diabetes. Future areas of focus include:

Identification of Novel Genetic Markers: Discovering additional genetic variants that contribute to diabetes risk, especially in underrepresented populations.

Gene Therapy: Advances in gene editing technologies, such as CRISPR-Cas9, may offer potential therapeutic avenues for treating monogenic forms of diabetes.

Epigenetic Therapies: Targeting epigenetic modifications to prevent or treat diabetes is a promising area of research, particularly in T2D.

Precision Medicine: Integrating genetic, epigenetic, and environmental data to develop personalized prevention and treatment strategies for diabetes.

CONCLUSION

The relationship between genetics and diabetes is a multifaceted and evolving area of research that plays a critical role in understanding the onset, progression, and treatment of the disease. This review has examined the genetic basis of various forms of diabetes, including Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and monogenic forms such as Maturity Onset Diabetes of the Young (MODY) and neonatal diabetes. It is clear that while environmental and lifestyle factors significantly contribute to the manifestation of diabetes, genetic predisposition is a central factor in determining individual susceptibility. In T1D, specific genetic loci, particularly within the HLA complex, predispose individuals to autoimmune destruction of pancreatic beta cells. T2D, on the other hand, is a polygenic disorder influenced by multiple genes, such as TCF7L2 and PPARG, which contribute to insulin resistance and glucose regulation. Monogenic forms of diabetes, like MODY and neonatal diabetes, offer a unique perspective on diabetes caused by single-gene mutations, where genetic testing can directly inform personalized treatment strategies. Epigenetic modifications and gene-environment interactions further complicate the genetic landscape of diabetes, with emerging research highlighting how external factors like diet and physical activity can alter gene expression, influencing disease development and progression. Personalized medicine, which leverages genetic testing and pharmacogenomics, is poised to revolutionize diabetes care by enabling more precise diagnosis, treatment, and prevention strategies based on individual genetic profiles.

Looking forward, the identification of novel genetic markers, advancements in gene therapy, and epigenetic treatments hold promise for improving diabetes management. As research continues to explore the genetic underpinnings of diabetes, personalized and precision medicine will become increasingly central to effectively addressing this complex and widespread disease.

REFERENCES

1. Barroso, I., & McCarthy, M. I. (2022). "Genetic variation in insulin resistance and its impact on type 2 diabetes." Clinical Science, 136(12), 923-937. https://doi.org/10.1042/CS20210784
2. Aja, P. M., Igwenyi, I. O., Ugwu, O. P. C., Orji, O. U., Alum, E. U. Evaluation of Anti-diabetic Effect and Liver Function Indices of Ethanol Extracts of Moringa oleifera and Cajanus cajan Leaves in Alloxan Induced Diabetic Albino Rats. Global Veterinaria. 2015;14(3): 439-447. DOI: 10.5829/idosi.gv.2015.14.03.93129.
3. Ugwu, O. P.C., Alum, E. U., Obeagu, E. I, Okon, M. B., Aja, P. M., Samson, A. O., Amusa, M. O. and Adepoju, A. O. Effect of

Ethanol Leaf extract of Chromolaena odorata on hepatic markers in streptozotocin-induced diabetic Wistar albino rats. IAA Journal of Applied Sciences, 2023; 9(1):46-56. https://doi.org/10.5281/zenodo.7811625

4. Egwu, C. O., Offor, C. E. and Alum, E. U. Anti-diabetic effects of Buchholzia coriacea ethanol seed Extract and Vildagliptin on Alloxan-induced diabetic albino Rats. International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS). 2017; 6 (6): 1304-1314. www.ijbpas.com. https://ijbpas.com/pdf/2017/June/1497506120MS%20IJBPAS%202017%204202.pdf
5. Ugwu O, P, C., Alum, E, U., Obeagu, E, I., Okon, M, B., Aja, P, M., Samson, A, O., Amusa, M, O., Adepoju, A, O. Effect of Ethanol leaf extract of Chromolaena odorata on lipid profile of streptozotocin induced diabetic Wistar albino rats.IAA Journal of Biological Sciences. 2023;10(1):109-117. https://www.iaajournals.org/wp-content/uploads/2023/03/IAAJB-101109-117-2023-Effect-of-Ethanol-leaf-extract-of-Chromolaena-odorata-on-lipid-profile-of-streptozotocin-induced-diabetic-wistar-albino-rats..docx.pdf.
6. Ezeani, N, N., Edwin, N., Alum, E, U., Orji, O, U, Ugwu, O, P, C., Effect of Ethanol Leaf Extract of Ocimum gratissmum (Scent Leaf) on Lipid Profile of Alloxan-Induced Diabetic Rats. International Digital Organization for Scientific Research Journal of Experimental Sciences, 2017; 2 (1): 164-179. www.idosr.org. https://www.idosr.org/wp-content/uploads/2017/07/IDOSR-JES-21-164-179-2017.-ezeani-2-updated.pdf
7. Flannick, J., & Johansson, S. (2022). "The genetics of type 2 diabetes and related traits." Nature Reviews Genetics, 23(2), 89-101. https://doi.org/10.1038/s41576-021-00409-8
8. Thomas, N. J., & Jones, A. G. (2023). "Monogenic diabetes: genetic insights and clinical implications." Journal of Clinical Investigation, 133(2), e156520. https://doi.org/10.1172/JCI156520
9. Robertson, C. C., & Steck, A. K. (2022). "Genetic risk scores in type 1 diabetes: State of the art and clinical applications." Diabetes Care, 45(9), 1873-1883. https://doi.org/10.2337/dc21-2057
10. Ezeani, N, N., Alum, E, U., Orji, O, U., Edwin, N. The Effect of Ethanol Leaf Extract of Pterocarpus santalinoids (Ntrukpa) on the Lipid Profile of Alloxan-Induced Diabetic Albino Rats. International Digital Organization for Scientific Research Journal of Scientific Research. 2017; 2 (2): 175-189. www.idosr.org. https://www.idosr.org/wp-content/uploads/2017/07/IDOSR-JSR-22-175-189-2017-EZEANI-updated.pdf
11. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I., Aja, P. M., Ugwu, C. N., Okon, M.B. Nutritional Care in Diabetes Mellitus: A Comprehensive Guide. International Journal of Innovative and Applied Research. 2023; 11(12):16-25. Article DOI: 10.58538/IJIAR/2057 DOI URL: http://dx.doi.org/10.58538/IJIAR/2057.
12. Ugwu, O.P.C., Kungu, E., Inyangat, R., Obeagu, E. I., Alum, E. U., Okon, M. B., Subbarayan, S. and Sankarapandiyan, V. Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR Experimental Sciences.2023; 12(2):214-224. https://doi.org/10.59298/INOSRES/2023/2.17.1000.
13. Kwak, S. H., & Cho, Y. M. (2023). "Recent advances in understanding the genetic basis of type 2 diabetes." Journal of Diabetes Investigation, 14(2), 91-103. https://doi.org/10.1111/jdi.13788
14. Rasmussen, T., & Ekstrøm, C. T. (2022). "Epigenetic mechanisms in type 2 diabetes: Focus on DNA methylation and histone modification." Nature Communications, 13(1), 1078. https://doi.org/10.1038/s41467-022-28718-6
15. Obeagu, E. I., Ugwu, O. P. C., Alum, E. U. Poor glycaemic control among diabetic patients; A review on associated factors. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023; 3(1):30-33. https://nijournals.org/newport-international-journal-of-research-in-medical-sciences-nijrms-volume-3-issue-1-2023/.

16. Aja, P. M., Ani, O. G., Offor, C. E., Orji, U. O., Alum, E. U. Evaluation of Anti-Diabetic Effect and Liver Enzymes Activity of Ethanol Extract of Pterocarpus santalinoides in Alloxan Induced Diabetic Albino Rats. Global Journal of Biotechnology & Biochemistry. 2015;10 (2): 77-83. DOI: 10.5829/idosi.gjbb.2015.10.02.93128.
17. Polak, M., & Hattersley, A. T. (2023). "Molecular insights into monogenic diabetes: From diagnosis to therapy." Current Opinion in Pediatrics, 35(3), 362-368. https://doi.org/10.1097/MOP.0000000000001251
18. Thomas, N. J., & Weedon, M. N. (2022). "The emerging role of genetics in diabetes management." Nature Reviews Endocrinology, 18(8), 485-496. https://doi.org/10.1038/s41574-022-00688-5
19. Balduzzi, D., & Gupta, R. (2023). "Epigenetics and gene-environment interactions in the pathogenesis of type 1 diabetes." Frontiers in Endocrinology, 14, 120335. https://doi.org/10.3389/fendo.2023.120335
20. Barroso, I., & Wheeler, E. (2023). "Genetic testing for diabetes risk and diagnosis: A path toward precision medicine." Journal of Endocrinology and Metabolism, 67(1), 14-25. https://doi.org/10.1210/jcem/bgaa689
21. Agbafor, K. N., Onuoha, S. C., Ominyi, M. C., Orinya, O. F., Ezeani, N. and Alum, E. U. Antidiabetic, Hypolipidemic and Antiathrogenic Properties of Leaf Extracts of Ageratum conyzoides in Streptozotocin-Induced diabetic rats. International Journal of Current Microbiology and Applied Sciences. 2015; 4 (11):816-824. http://www.ijcmas.com. https://www.ijcmas.com/vol-4-11/Agbafor,%20K.%20N,%20et%20al.pdf
22. Uti, D. E., Igile, G. O., Omang, W. A., Umoru, G. U., Udeozor, P. A., Obeten, U. N., Ogbonna, O. N., Ibiam U. A., Alum, E. U.,Ohunene, O. R., Chukwufumnanya, M. J., Oplekwu, R. I. and Obio, W. A.Anti-Diabetic Potentials of Vernonioside E Saponin; A Biochemical Study. Natural Volatiles and Essential Oils. 2021; 8(4): 14234-14254.
23. Alum, E. U., Umoru, G. U., Uti, D. E., Aja, P. M., Ugwu, O. P., Orji, O. U., Nwali, B. U., Ezeani, N., Edwin, N., Orinya, F. O. Hepato-protective effect of Ethanol Leaf Extract of Datura stramonium in Alloxan-induced Diabetic Albino Rats. Journal of Chemical Society of Nigeria. 2022; 47 (3): 1165 – 1176. https://doi.org/10.46602/jcsn.v47i5.819.
24. Ugwu, O. P.C., Alum, E. U., Okon, M. B., Aja, P. M., Obeagu, E. I. and Onyeneke, E. C. Ethanol root extract and fractions of Sphenocentrum jollyanum abrogate hyperglycemia and low body weight in Streptozotocin-induced diabetic Wistar albino Rats, RPS Pharmacy and Pharmacology Reports. 2023; 2,1-6.https://doi.org/10.1093/rpsppr/rqad010.
25. Offor, C. E., Ugwu, O. P. C., Alum, E. U. The Anti-Diabetic Effect of Ethanol Leaf-Extract of Allium sativum on Albino Rats. International Journal of Pharmacy and Medical Sciences. 2014; 4 (1): 01-03. DOI: 10.5829/idosi.ijpms.2014.4.1.1103.
26. Obeagu, E. I., Scott, G. Y., Amekpor, F., Ugwu, O. P. C., Alum, E. U. COVID-19 infection and Diabetes: A Current Issue. International Journal of Innovative and Applied Research. 2023; 11(01): 25-30. DOI: 10.58538/IJIAR/2007. DOI URL: http://dx.doi.org/10.58538/IJIAR/2007.
27. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Beyond Pregnancy: Understanding the Long-Term Implications of Gestational Diabetes Mellitus. INOSR Scientific Research. 2024; 11(1):63-71.https://doi.org/10.59298/INOSRSR/2024/1.1.16371
28. Ugwu, O. P. C., Alum, E. U. and Uhama, K. C. (2024). Dual Burden of Diabetes Mellitus and Malaria: Exploring the Role of Phytochemicals and Vitamins in Disease Management. Research Invention Journal of Research in Medical Sciences. 3(2):38-49.

CITE AS: Kibibi Muthoni L. (2024). The Relationship between Genetics and Diabetes: A Comprehensive Review. IAA Journal of Scientific Research 11(3):7-13. https://doi.org/10.59298/IAAJSR/2024/113.713